| 1 |
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill F. Hallin et al. · Cancer Discovery
Open access |
28 Oct 2019 |
1,328 |
| 2 |
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Pasi Antero Janne et al. · New England Journal of Medicine
Open access |
3 Jun 2022 |
1,051 |
| 3 |
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Xiaolun Wang et al. · Journal of Medicinal Chemistry
Open access |
10 Dec 2021 |
754 |
| 4 |
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark Magdi Awad, Geoffrey R. Oxnard, David Michael Jackman et al. · Journal of Clinical Oncology
Open access |
5 Jan 2016 |
706 |
| 5 |
Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell et al. · Journal of Medicinal Chemistry
Open access |
6 Apr 2020 |
627 |
| 6 |
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Jill F. Hallin et al. · Nature Medicine
|
Oct 2022 |
549 |
| 7 |
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Rona D. Yaeger, Jared Weiss, Meredith S. Pelster et al. · New England Journal of Medicine
Open access |
21 Dec 2022 |
524 |
| 8 |
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber et al. · Journal of Clinical Oncology
Open access |
6 Apr 2017 |
475 |
| 9 |
Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette Marie Sholl et al. · JCI Insight
Open access |
16 Nov 2016 |
458 |
| 10 |
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Samantha B. Kemp et al. · Cancer Discovery
Open access |
6 Dec 2022 |
382 |
| 11 |
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)
Sai‐Hong Ignatius Ou, Pasi Antero Janne, Ticiana A.B. Leal et al. · Journal of Clinical Oncology
Open access |
15 Feb 2022 |
316 |
| 12 |
Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Tanios Bekaii‐Saab, Rona D. Yaeger, Alexander I. Spira et al. · Journal of Clinical Oncology
Open access |
26 Apr 2023 |
306 |
| 13 |
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly et al. · Cancer Discovery
Open access |
5 Jul 2024 |
273 |
| 14 |
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
Lars D. Engstrom et al. · Cancer Discovery
Open access |
8 Aug 2023 |
219 |
| 15 |
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Al B. Benson et al. · Journal of the National Comprehensive Cancer Network
Open access |
Jul 2023 |
213 |
| 16 |
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere, Shuai Li, Andrew Calinisan et al. · Molecular Cancer Therapeutics
Open access |
15 Mar 2021 |
175 |
| 17 |
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP -Deleted Cancers
Christopher R. Smith et al. · Journal of Medicinal Chemistry
Open access |
18 Jan 2022 |
161 |
| 18 |
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D. Engstrom et al. · Clinical Cancer Research
|
Aug 2017 |
150 |
| 19 |
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Rona D. Yaeger et al. · Cancer Discovery
Open access |
10 Nov 2022 |
148 |
| 20 |
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy
David M. Briere, Niranjan Sudhakar, David Michael Woods et al. · Cancer Immunology Immunotherapy
Open access |
9 Nov 2017 |
146 |
| 21 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma
Timothy Francis Cloughesy et al. · JAMA Oncology
Open access |
29 Oct 2020 |
145 |
| 22 |
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
Pasi Antero Janne, Igor I. Rybkin, Alexander I. Spira et al. · European Journal of Cancer
|
Oct 2020 |
141 |
| 23 |
“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas
Rajan Jain, Derek Richard Johnson, Sohil Harshad Patel et al. · Neuro-Oncology
Open access |
13 Feb 2020 |
139 |
| 24 |
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Joshua K. Sabari, Vamsidhar Velcheti, K. Shimizu et al. · Clinical Cancer Research
Open access |
11 Apr 2022 |
135 |
| 25 |
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong et al. · Cancer Cell
Open access |
22 Feb 2024 |
132 |
| 26 |
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Jeffrey A. Klomp et al. · Science
Open access |
6 Jun 2024 |
121 |
| 27 |
Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial
Robert K. Naviaux, Brooke Curtis, Kefeng Li et al. · Annals of Clinical and Translational Neurology
Open access |
26 May 2017 |
112 |
| 28 |
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay et al. · Cancer Research
Open access |
20 Sep 2023 |
111 |
| 29 |
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B. Fell et al. · ACS Medicinal Chemistry Letters
Open access |
7 Nov 2018 |
111 |
| 30 |
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
Connie Lee Batlevi, Michael Crump, Charalambos Babis Andreadis et al. · British Journal of Haematology
Open access |
25 Apr 2017 |
109 |
| 31 |
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Kwan Ho Tang, Shuai Li, Alireza Khodadadi-Jamayran et al. · Cancer Discovery
Open access |
5 Aug 2021 |
105 |
| 32 |
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Hossein Borghaei et al. · Annals of Oncology
Open access184 authors |
20 Oct 2023 |
102 |
| 33 |
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction
John M. Ketcham et al. · Journal of Medicinal Chemistry
Open access |
14 Jul 2022 |
96 |
| 34 |
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
A. Cole Edwards, Clint A. Stalnecker, Alexis Jean Morales et al. · Cancer Research
Open access |
7 Nov 2023 |
90 |
| 35 |
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
Erik S. Linklater, Elizabeth A. Tovar, Curt J. Essenburg et al. · Oncotarget
Open access |
16 Sep 2016 |
84 |
| 36 |
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C -Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
Marcelo Vailati Negrao, Alexander I. Spira, Rebecca Suk Heist et al. · Journal of Clinical Oncology
Open access |
16 Jun 2023 |
82 |
| 37 |
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Anupriya Singhal, Hannah C. Styers, Jonathan Rub et al. · Cancer Discovery
Open access |
5 Jul 2024 |
80 |
| 38 |
99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
G.J. Riely, S-H.I. Ou, Igor I. Rybkin et al. · Journal of Thoracic Oncology
Open access |
27 Mar 2021 |
80 |
| 39 |
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
Melissa Lynne Johnson, S.-H.I. Ou, Minal A. Barve et al. · European Journal of Cancer
|
Oct 2020 |
79 |
| 40 |
Targeting Krasg12c‐mutant cancer with a mutation‐specific inhibitor
James G. Christensen, Peter Olson, Tina Marie Briere et al. · Journal of Internal Medicine
Open access |
16 Mar 2020 |
76 |
| 41 |
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun‐Hao Pan et al. · Cancer Discovery
Open access |
6 Nov 2023 |
75 |
| 42 |
LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
J.M. Weiss, Rona D. Yaeger, Melissa Lynne Johnson et al. · Annals of Oncology
Open access |
Sep 2021 |
74 |
| 43 |
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
Pavlos Msaouel et al. · Science Translational Medicine
Open access |
20 Apr 2022 |
67 |
| 44 |
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
Manoj Kumar Kashyap, Carlos I. Amaya-Chanaga, Deepak Kumar et al. · Journal of Hematology & Oncology
Open access |
19 May 2017 |
64 |
| 45 |
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
Fabrice Barlési et al. · The Lancet
207 authors |
Aug 2025 |
60 |
| 46 |
LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Marina Chiara Garassino, Willemijn S.M.E. Theelen, Robert M. Jotte et al. · Annals of Oncology
Open access |
Oct 2023 |
54 |
| 47 |
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
Marc Oliva et al. · Journal for ImmunoTherapy of Cancer
Open access |
Oct 2021 |
53 |
| 48 |
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
Petros D. Grivas, Amir Mortazavi, Joel Picus et al. · Cancer
Open access |
20 Dec 2018 |
53 |
| 49 |
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
Jose Antonio Karam et al. · Nature Communications
Open access |
10 May 2023 |
49 |
| 50 |
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis
Subrata K. Ghosh, Brian G. Feagan, Elyssa Ott et al. · Journal of Crohn s and Colitis
Open access |
2 Feb 2024 |
45 |